+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
A

Actively Recruiting

Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
60 locations
E

Actively Recruiting

Researchers are studying solbinsiran, a drug given by injection, to see how well it lowers triglycerides and other blood fat levels in adults with severe hypertriglyceridemia. This phase 2 study compares solbinsiran to a placebo to evaluate safety and effectiveness in this condition. Participants will receive two subcutaneous injections of either solbinsiran or placebo. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period includes regular assessments of lipid levels over approximately 16 to 24 weeks. During the study, participants will have blood tests to measure triglycerides and related lipid markers at baseline and follow-up visits. Researchers will also monitor drug levels in the blood to understand how the body processes solbinsiran. The main outcome is the change in triglyceride levels from the start to weeks 16-24. Safety and other lipid changes will be followed until the study ends around August 2027.

Age: 18Years +All GendersPhase 2
41 locations